Sarah Moyle

Sarah Moyle acts as Head of International Relations at Medtech Switzerland in addition to completing her PhD in Biomedical Science from the University of Bern.  She has managed the publication and content of numerous economic reports on the medical technology industry including country-specific reports for the Chinese, Russian, Swiss, and Japanese medtech and device markets. Ms Moyle holds a master's degree in physiology from the University of Colorado at Boulder and has worked with pharmaceutical and medical device and technology companies both in the US and Switzerland fulfilling roles in clinical studies, marketing, and usability. 

In the past few weeks, the Swiss newspapers have been littered with an uncomfortable and poisonous prospect: the U.S. A financial force banging its chest from its modest economic recovery is demanding tax justice from Switzerland. The stable currency, neutrality and talented investment acumen that the Swiss have quietly touted to global investors has allowed them to amass some 30-40% of foreign investments. Now the tables are turning. With increasing pressure from the U.S., Switzerland is about to be forced into giving up one of its oldest and most sacred treasures - the hidden, numbered, off-shore Swiss bank accounts. So far this only seems to be relevant to U.S. account holders, but the vultures are already beginning to circle. France, Germany and the U.K. will almost certainly follow suit once the dust clears and the stage opens up for more opportunistic assaults on secret Swiss accounts.